ERAS Financials | Income, Balance Sheet & Cash Flow
The financial statements for ERAS (ERAS) provide a snapshot of revenue trends, balance-sheet strength, and cash flow quality. Reviewing these together helps investors evaluate earnings durability, capital structure, and whether operating cash flow supports long-term business growth.
See stock fair value and complete historical financials—premium unlocks deeper tables and metrics.
Financial Statements
Related peers
Compare More →| ARVN Arvinas, Inc. | $10.97 -0.27% |
| CTMX CytomX Therapeutics, Inc. | $4.56 +0.44% |
| CRVS Corvus Pharmaceuticals, Inc. | $15.11 -0.92% |
| MLTX MoonLake Immunotherapeutics | $18.02 -4.05% |
| R Ryder System, Inc. | $212.05 -3.54% |
| MGTX MeiraGTx Holdings plc | $11.25 -0.35% |
| Peer | Price | Change | Market Cap | PE | EPS | Div Yield (TTM) | Analyst Rating | Volume |
|---|---|---|---|---|---|---|---|---|
| ARVN Arvinas, Inc. | $10.97 | -0.27% | 704.54 M | -9.22 | -1.19 | 0.00% | Hold | 603 |
| CTMX CytomX Therapeutics, Inc. | $4.56 | +0.44% | 776.34 M | -30.40 | -0.15 | 0.00% | Buy | 4.69 |
| CRVS Corvus Pharmaceuticals, Inc. | $15.11 | -0.92% | 1.27 B | -28.51 | -0.53 | 0.00% | Buy | 898 |
| MLTX MoonLake Immunotherapeutics | $18.02 | -4.05% | 1.29 B | -5.10 | -3.53 | 0.00% | Buy | 1.08 |
| R Ryder System, Inc. | $212.05 | -3.54% | 8.36 B | 17.67 | 12.00 | 0.86% | Buy | 556 |
| MGTX MeiraGTx Holdings plc | $11.25 | -0.35% | 916.27 M | -7.92 | -1.42 | 0.00% | Buy | 643 |
Frequently Asked Questions
What are ERAS's latest financial results?
Review ERAS's latest balance sheet, income statement, and cash flow to understand its profitability, revenue trends, and financial health. These metrics are essential for evaluating short-term performance and long-term stability.
How has ERAS's revenue and net income changed over time?
Analyzing historical revenue and net income shows growth trends and business performance. Consistent growth indicates operational strength, while declines may signal challenges that investors should consider.
What is ERAS's cash flow situation and liquidity?
Cash flow statements reveal how ERAS generates and uses cash. Strong operating cash flow and sufficient liquidity suggest the company can fund operations, pay dividends, and handle debt effectively.
How does ERAS's financial performance compare to industry peers?
Comparing key metrics like revenue growth, profit margins, and debt levels with competitors helps investors assess whether ERAS is outperforming or lagging within its sector.
Are ERAS's financial statements showing sustainable profitability?
By analyzing margins, ROE, ROIC, and cash generation over multiple periods, investors can evaluate whether ERAS's profits are repeatable and supported by strong fundamentals.